Throughout 2026, tariffs, inflation, and shifting geopolitical dynamics have added additional pressure to medtech supply chains, with the diabetes technology supply chain being no exception.
For diabetes technology, these factors are reshaping where devices are made, how they’re priced, and ultimately, which products reach patients. On 18 August, GlobalData Healthcare analysts Dr Andrew Thompson, director of therapy research and analysis, medical devices, and Charlie Whelan, senior director of consulting, medical devices, will host a webinar assessing the impact these challenges.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
During the “Lifting the Lid on the Diabetes Tech Supply Chain” webinar, Thompson and Whelan will draw on revenue and volume data across the diabetes device market to show how macroeconomic forces translate into real commercial and patient-level outcomes.
Topics under assessment will include how globalised manufacturing across the diabetes device market creates exposure to tariff and inflation risk, where revenue and volume flows sit today, and the relationship between gate pricing and macroeconomics, with Thompson and Whelan assessing what these factors mean for manufacturers, payers, and patients as geopolitical uncertainty continues.
Keen to learn more about how market challenges are impacting pricing and production dynamics in the diabetes technology supply chain?
Register for our webinar, taking place 18 August at 3:00pm BST, at the link below:
https://globaldata.zoom.us/webinar/register/6917834313659/WN_rnGlEFywRzqHC1q2Av9jnw
